Search results
Martin Hutchings, MD, PhD. Dr. Martin Hutchings received his medical degree and his PhD at the University of Copenhagen, Denmark. He is a staff specialist, Department of Hematology, at the Finsen Centre, National Hospital, Copenhagen University Hospital in Denmark.
Martin HUTCHINGS, Senior consultant | Cited by 9,901 | of Rigshospitalet, Copenhagen (rigshospitalet) | Read 243 publications | Contact Martin HUTCHINGS
Rigshospitalet - Cited by 14,157
Senior Consultant, PhD. Affiliated to. Department of Haematology and Phase 1 Unit, Centre for Cancer and Organ Diseases and Department of Clinical Medicine, University of Copenhagen. Research areas include. Clinical and translational studies of malignant lymphoma. Haematology phase 1 studies.
Dec 8, 2023 · Management of hematological malignancies is rapidly evolving from chemotherapy-based regimens toward targeted agents and immunotherapies, including bispecific antibodies (BsAbs). These novel and highly active treatments come with new side effect profiles.
Martin Hutchings, MD, PhD, of Copenhagen University Hospital, discusses a 5-year update of the phase III ECHELON-1 study, which suggested brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine benefits patients with previously untreated stage III or IV classical Hodgkin lymphoma (Abstract S205).
Dec 10, 2023 · Subcutaneous epcoritamab in R/R B-cell NHL. Martin Hutchings speaks exclusively to VJHemOnc , The Video Journal of Hematological Oncology. Watch interviews and discussions with Martin Hutchings here.
